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Summary
Multicentric carpotarsal osteolysis (MCTO) is an autoso-
mal dominant disease of the skeleton characterised by
progressive destruction of carpal and tarsal bones. Re-
cently, it has been demonstrated that this disease is
caused by heterozygous mutations in the gene for the
transcriptional repressor MAFB. We analysed genomic
DNA and RNA from leucocytes of a female patient diag-
nosed with MCTO. We identified the mutation c.161C>T in
the genomic sequence and in the expressed messenger
RNA for MAFB. This is the second report of the c.161C>T
mutation in a MCTO patient. Since the parents do not pos-
sess this mutation, the daughter must have acquired a de
novo mutation. At the level of the gene, this mutation is
found at a CpG dinucleotide sequence, suggesting that
DNA methylation was involved in the occurrence of the
DNA aberration. At the level of the protein, the mutation
exchanges a serine with a leucine residue at a position
on MAFB that can become phosphorylated in the wild-
type protein. MAFB negatively regulates the RANKL-de-
pendent differentiation of monocytes into osteoclasts. It
is likely that the mutation will affect the phosphorylation
status of the protein and its biological activity. When the
activity of the transcriptional repressor is reduced, osteo-
clastogenesis will be increased, which might explain the
carpotarsal bone destruction observed in the patient.
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Introduction
Multicentric carpotarsal osteolysis (MCTO, MIM 166300)
is a rare disease of the skeleton characterised by aggressive
destruction and disappearance of the carpal and tarsal
bones, with other bones, including the metacarpals, being
barely affected. Often, the patients show slight craniofacial
abnormalities such as micrognathia and a triangle face, and
frequently they develop a progressive nephropathy, which
may lead to renal failure. The disease can be inherited in
an autosomal dominant fashion, although most of the cases
appear to represent sporadic events that are caused by de
novo mutations [1–3].
In 2012, Zankl et al. [1] carefully analysed 11 simplex cas-
es with MCTO as well as two families with autosomal
dominant MCTO. By next-generation sequencing, the au-
thors identified ten different missense mutations in the
gene for the transcription factor MAFB. All these muta-
tions were found in a short region of 51 base-pairs, corre-
sponding to the amino terminal transactivation domain of
the transcription factor. The results were subsequently con-
firmed by Mehawej et al. [2], who studied eight MCTO
cases from six families, and by Mumm et al. [3], who stud-
ied nine MCTO patients from eight families.
MAFB is a member of the MAF family of basic leucine
zipper transcription factors [4, 5]. This family includes
seven members, four large MAF proteins (MAFA, MAFB,
c-MAF and NRL) and three small MAF proteins (MAFG,
MAFF, MAFK) that lack the transactivation domain. The
MAF proteins belong to the activator protein-1 (AP1) su-
perfamily of transcription factors, which are known to
form homo- and heterodimers via an extended leucine zip-
per [6]. The basic domain that precedes this leucine zipper
enables the interaction of the protein with the MAF recog-
nition element (MARE) on target genes. MAFB can form
dimers with many other AP1 members (MAFA, MAFB, c-
MAF, FOS, FOSB, FRA1, FRA2, JUN, BACH1) and as
a consequence it is involved in the development of many
organs and tissues. Experiments with mice and chickens
have demonstrated that MAFB is involved in the segmen-
tation of the hindbrain [7], in the differentiation of pancre-
atic β-cells [8], in the survival of podocytes in the kidney
[9] and in the differentiation of monocytes [10].
In the haematopoietic system, MAFB is specifically ex-
pressed in the myeloid lineage that includes monocytes,
macrophages and osteoclasts. It appears to induce the dif-
ferentiation of multipotent progenitor cells into monocytes
and macrophages [10], but to negatively regulate the dif-
ferentiation into osteoclasts [11]. The negative regulation
is accomplished by inhibiting RANKL-mediated osteo-
clastogenesis at the transcriptional level via binding to
transcription factors FOS and MITF. Mutations in MAFB,
as found in MCTO patients, might therefore release the
block of osteoclast differentiation.
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Materials and methods
Isolation of genomic DNA
DNA was purified from freshly drawn blood with use of
the Wizard genomic DNA purification kit from Promega
(Madison, WI, USA). Written consent was obtained from
all probands to use the samples for genetic testing and to
publish the results in accordance with the guidelines of the
Swiss Society of Medical Genetics. Red blood cells were
removed by specific cell lysis. White blood cells were col-
lected by centrifugation and lysed in Nuclei Lysis Solu-
tion. RNA was digested with RNase and cellular proteins
were removed by salt precipitation. Finally, the genomic
DNA was precipitated with isopropanol and washed with
ethanol.
RNA isolation
Total RNA was extracted from blood by means of the QI-
Aamp RNA Blood Mini kit from Qiagen (Hilden, Ger-
many). Samples of fresh blood (2 ml) were collected in
the presence of the anticoagulant EDTA and immediately
processed. Erythrocytes were lysed in hypotonic buffer.
Leucocytes were collected by centrifugation, lysed with a
QIAshredder and dissolved in RLT buffer. The RNA was
adsorbed to a silica membrane, washed and eluted with TE
buffer. The purified RNA was transcribed into first-strand
cDNA using random hexamer primers and Improm-II Re-
verse Transcriptase (Promega, Madison, WI, USA).
PCR amplification and DNA sequencing
Fragments of interest were amplified via the polymerase
chain-reaction (PCR) through 35 cycles (20" at 98°C, 15"
at 65°C, 15–50'' at 72°C) with KAPA high fidelity DNA
polymerase (KAPA Biosystems, Boston, USA). The fol-
lowing primer pairs were used: ACGTGAAGAAGGAGC-
CACTG / TGTGTCTTCTGTTCGGTCGG (product 154
bp), AGAGCAAGAGAGCTAGAGAGC / ATGGC-
CTTCCTGACTTCTCG (product 1647 bp). The fragments
were separated on 1% agarose gels. Resolved fragments
were recovered from the gels with the GeneElute extrac-
tion kit (Sigma, St. Louis, MO, USA). DNA sequences
were determined by Sanger cycle sequencing on an ABI
3730 platform and analysed with the program package of
MacVector Inc. (Apex, NC, USA).
Parental DNA testing
To unequivocally prove a parental relationship between fa-
ther, mother and daughter, DNA profiling was done with
a set of informative microsatellite markers. Genomic DNA
of father, mother and daughter was used to amplify 15
highly polymorphic short tandem repeats (STRs) with the
PowerPlex® 16 HS System (Promega, Madison, WI,
USA). The STRs included D3S1358, TH01, D21S11,
D18S51, D5S818, D13S317, D7S820, D16S539,
CSF1PO, vWA, D8S1179, TPOX, FGA, PentaD and Pen-
taE. The PCR fragments were resolved by capillary elec-
trophoresis on a 3730xl DNA analyser (ABI Life Tech-
nologies, Thermo Fisher Scientific, Waltham, MA, USA)
and the resulting data were analysed with the GeneMark-
er® HID software from SoftGenetics (State College, PA,
USA).
Results
The female patient, who is currently 20 years old, devel-
oped pain of her right wrist at the age of 4 years. She
received intra-articular injections of glucocorticoids, fol-
lowed by weekly doses of methotrexate. Because of pro-
gressive joint erosions, the tumour necrosis factor blocker
etanercept was added at the age of 7 years. Bone destruc-
tion progressed despite therapy and a histological exami-
nation showed activated osteoclasts and signs of fibrosis.
Concomitant proteinuria prompted a kidney biopsy at the
age of 13 years, which revealed low-grade focal glomeru-
losclerosis that finally led to the diagnosis of carpotarsal
osteolysis with nephropathy (MCTON). Blood levels of
calcium, phosphate, vitamin D3 and parathyroid hormone
were normal. A tarsal bone biopsy at the age of 18 showed
enhanced bone resorption and fibrosis. A single dose of
denosumab (60 mg) was able to reduce the inflammation
as demonstrated with magnetic resonance imaging (MRI)
9 months later.
The course of the carpal bone destruction is presented in
fig. 1. At the age of 5, the index patient possessed all
carpal bones, but some alterations in location and orien-
tation were evident. At the age of 10, the carpal bones
showed erosions and partial destruction. At 13 years, the
carpal bones and the epiphyses of the ulna and radius
were almost completely resorbed. At 16 years, the proxi-
mal ends of the metacarpals showed progressive thinning
and sclerosis, with ulnar deviation in the left hand. The
tarsal bones revealed multilocular erosions at the age of 9
years. In contrast to the carpal bones, they did not become
resorbed, but the erosions led to osteoarthritis (not shown).
A pedigree of the family of the index patient is presented
in fig. 2. Neither the parents nor the brother showed any
signs of the disease. A careful analysis of 15 different mi-
crosatellite markers proved that the parents were in fact
the biological parents of the index patient (probability of
parental offspring >99.9999%). Our MCTO patient must
therefore have acquired a de novo mutation.
Genomic DNA and total RNA were isolated from leuco-
cytes of freshly drawn blood. Sequencing of the single ex-
on of MAFB on both strands of the genomic DNA revealed
the heterozygous mutation c.161C>T (fig. 3). At the pro-
tein level, this mutation led to the substitution of serine-54
in MAFB by leucine (p.S54L). Neither father nor moth-
er carried this mutation, confirming the presence of a de
novo mutation (fig. 3). Quantification of the areas under
the chromatogram of the index patient revealed 49% C and
51% T (n = 3), indicating complete penetrance of the het-
erozygous disease in leucocytes. Sequencing of the MAFB
mRNA after reverse transcription into cDNA proved the
same c.161C>T mutation. Quantification of the areas un-
der the chromatogram revealed a similar proportion of C
and T (47% C, 53% T), suggesting that the two alleles of
the MAFB gene were transcribed into mRNA with similar
efficiency (not shown).
Discussion
The genetic cause of MCTO was discovered 5 years ago
when Zankl et al. [1] reported that patients diagnosed with
the disease contain mutations in the gene for the transcrip-
tional repressor MAFB. So far, 15 different missense mu-
tations that affect the codons for 10 different amino acids
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Figure 1: Phenotype of the patient. X-ray images of the hands were taken approximately every 4 years. At the age of 5 years, all carpal
bones were present but thereafter, they were gradually resorbed and were completely lost at about 16 years of age. Note that most of the oth-
er bones are intact. Only the metacarpal bones are affected at regions where they touch the carpal bones.
have been reported [1–3]. All these mutations cluster in the
transactivation domain of MAFB, which is thought to in-
teract with other proteins of the transcription machinery.
Our patient has a heterozygous mutation at nucleotide-161
(c.161C>T), which changes serine-54 into leucine
(p.Ser54Leu). This is the second report of the c.161C>T
mutation in a MCTO patient; the same mutation was found
by Zankl et al. [1] in two families with autosomal dominant
Figure 2: Pedigree of the patient’s family. Individual members of
a family are numbered according to their relative age. The MCTO
phenotype is observed exclusively with the index patient 10.
MCTO. Furthermore, Mehawej et al. [2] described a dif-
ferent mutation at the same position (c.161C>G), which
changes serine-54 into tryptophan. Of note, all 15 muta-
tions described so far in MCTO patients are situated within
a short region of MAFB (residues 54-71) that can become
phosphorylated in the wild-type protein (fig. 4). This re-
gion encompasses eight serine and two threonine residues.
Experiments with a phospho-specific antibody showed that
at least two of these residues, T58 and T62, could be phos-
phorylated by glycogen synthase kinase-3 (GSK3) [12].
Phosphorylation has been studied in more detail with the
homologous protein MAFA. MAFA is phosphorylated on
residues S49, T53, T57, S61 and S65 in a sequential fash-
ion [13]. These residues correspond to S54, T58, T62, S66
and S70 in MAFB (fig. 4). Interestingly, phosphorylation
of MAFA increases its biological activity, but at the same
time induces its degradation [14]. Since the sequences of
MAFA and MAFB are highly conserved in this particular
region, it is likely that phosphorylation of S54 in MAFB,
which would correspond to the mutated site of our patient,
will also affect the activity of the protein.
MAFB is known as an important modulator of osteoclasto-
genesis. It induces development of monocytes from prog-
enitor cells [10], but at the same time inhibits their terminal
differentiation into active osteoclasts [11]. Osteoclastoge-
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Figure 3: Sequencing of the MAFB gene. Parts of the original sequencing chromatograms are shown together with the genomic DNA se-
quence and the predicted amino acid sequence. The patient reveals a C>T transition that is found on the coding as well as on the noncoding
strand. The heterozygous mutation substitutes a serine by a leucine residue. Note that neither father nor mother contains this mutation.
Figure 4: Alignment of the amino acid sequences of MAFA and MAFB from mice and humans at the region that is mutated in MCTO
patients. Identical residues are boxed. Serine and threonine residues, which can become phosphorylated by GSK3, are indicated by aster-
isks. The mutation of the index patient corresponds to serine-54, which represents the first of the five phosphorylation sites.
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nesis is controlled by the RANK/RANKL signalling path-
way [15]. RANKL-deficient mice show severe osteopet-
rosis with a complete lack of osteoclasts [16]. RANKL
overexpressing mice, in contrast, have an osteoporotic phe-
notype with loss of trabecular bone [17]. MAFB appears
to affect RANK/RANKL signalling by interfering at the
genomic level with the expression of transcription factors
NFATc1 and OSCAR. There is experimental evidence that
MAFB binds to the transcriptional activators FOS and
MITF and prevents them from binding to their target
genes, which would include NFTAc1 and OSCAR [11].
When MAFB activity is missing, FOS can interact with
NFATc1 and enhance transcription of NFATc1 in a positive
feedback loop, whereas MITF can combine with NFTAc1
and drive transcription of OSCAR. In combination, the two
proteins will induce the programme of osteoclast differen-
tiation and ultimately lead to the breakdown of bone.
Our patient must have acquired a de novo mutation since
the parents do not possess the mutation. This is in contrast
to the probands of the two families investigated by Zankl et
al., who obviously inherited the c.161C>T mutation from
one of their parents. This publication is therefore the first
description of a de novo mutation at this particular position
of the MAFB gene. It appears that this region represents
a hotspot for mutation. The codon for serine 54 (TCG)
contains a CpG dinucleotide, which can become methylat-
ed at the 5′ position of cytosine. DNA methylation is the
only major modification of the genomic DNA in humans
[18]. Typically, methylated regions of the DNA are inac-
tive and tightly packed into condensed heterochromatin,
whereas unmethylated regions are transcriptionally active.
Five-methylcytosine can spontaneously convert to thymine
[18, 19]. During evolution, the human genome has gradu-
ally lost most of its CpG dinucleotide sequences and those
CpG dinucleotides that persisted are mostly restricted to
CpG islands. Such islands are typically found at the 5′ re-
gions of genes (promoters), which interact with regulatory
factors that shield the DNA from methylation. In fact, our
CpG site is located in a CpG island that includes the 5′ half
of the MAFB gene (Fig. 5). This gene might stay free of
methylation during development when it is actively tran-
scribed. However, during spermatogenesis up to 90% of
the CpG dinucleotides become methylated in order to keep
mature sperm cells in a transcriptionally inactive state [20].
After modification, 5-methylcytosine can mutate with low
frequency to thymine and when this aberration is not re-
paired, the sperm cells incorporate a mutation that can be
passed on to the offspring. It is of interest to note that 5
out of the 15 MAFB mutations described today are C>T
transitions occurring at CpG dinucleotides. In fact, approx-
imately 37% of all point mutations responsible for genet-
ic human diseases are transitional mutations found at CpG
dinucleotides [21].
Why is the osteolysis in MCTO patients restricted to the
carpal and tarsal bones? What makes these bones so spe-
cial that they are completely resorbed while other bones,
including the metacarpals, are barely affected? Carpal
bones differ in at least two aspects from tubular bones, al-
though they too grow by endochondral ossification. Carpal
bones are spherical bones that grow on all sides, whereas
tubular bones are bipolar and grow only between the epi-
physis and the diaphysis. The term acrophysis has there-
fore been introduced for the growth plates of carpal and
tarsal bones [22]. Like the metaphysis of long bones, the
acrophysis contains cartilage cells, which are lined up in
defined layers (resting cells, zone of division, zone of co-
lumniation, hypertrophic zone and zone of calcification).
Acrophyses are not only found in carpal and tarsal bones
but also in the patella. In our patient, the patella is not af-
fected. Another difference between carpal bones and long
bones is the formation of multiple joints. Tubular bones
contain two regions that form joints with adjacent bones,
but carpal bones are involved in a large number of joints.
The human wrist is made up of eight bones that enable
articulation with the metacarpal bones of the digits, with
the radius and the ulna of the forearm and among them-
selves. Most of these bones (except the pisium) have six
surfaces. Three to four of these surfaces (depending on
whether they are in contact with contiguous bones) are ar-
ticular and consequently covered by hyaline cartilage. Lit-
tle is known about the molecular mechanisms that regu-
late the formation of such multiple joints. It is possible that
these mechanisms are responsible for the specific location
of the lesions observed in MCTO.
It remains to be demonstrated how all these findings would
translate into a better treatment of MCTO patients. At the
moment, the only feasible treatment appears to be the inhi-
bition of terminal differentiation of monocytes into osteo-
clasts. This can be achieved by the administration of neu-
tralising antibodies against RANKL such as denosumab.
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Figure 5: The mutation occurs in a typical CpG island. The frequency of CpG dinucleotides within a window of 200 is depicted along the
genomic sequence of human chromosome 20 at the region of the MAFB gene. A grey box shows the single exon of the MAFB gene. An arrow
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stream and downstream have a very low CpG content (0–3 CpG/200 nt).
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